Tuesday, November 12, 2024 5:14:51 PM
Thanks for the update.
Most is as expected. Details on the EU would have been nice.
Most is as expected. Details on the EU would have been nice.
Recent OTLK News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:04:56 PM
- Outlook Therapeutics Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 03/25/2026 08:05:00 PM
- Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering • GlobeNewswire Inc. • 03/24/2026 11:00:00 AM
- Outlook Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 03/23/2026 09:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/23/2026 09:18:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 01:00:28 PM
- Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note • GlobeNewswire Inc. • 03/16/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 08:30:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 10:01:18 PM
- Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 03/05/2026 09:15:00 PM
- Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland • GlobeNewswire Inc. • 02/19/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 10:01:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 10:01:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:30:36 PM
- Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/17/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 10:00:40 PM
- Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter • GlobeNewswire Inc. • 02/11/2026 01:45:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 01/26/2026 10:03:09 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2026 10:02:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2026 10:01:25 PM
- Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development • GlobeNewswire Inc. • 01/06/2026 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 12:30:35 PM
- Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD • GlobeNewswire Inc. • 12/31/2025 09:15:00 PM
- Outlook Therapeutics Announces New Employment Inducement Grants • GlobeNewswire Inc. • 12/26/2025 10:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/19/2025 10:01:45 PM
